Cargando…

Tolerability of Nasal Delivery of Humidified and Warmed Air at Different Temperatures: A Randomised Double-Blind Pilot Study

Objectives. Delivery of warmed, humidified air via nasal high flow therapy could potentially reduce replication of temperature-sensitive viruses in the upper respiratory tract. This study investigates whether nasal high flow therapy is well tolerated by healthy adults at 37°C and 41°C. Methods. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bibby, Susan, Reddy, Sumeet, Cripps, Terrianne, McKinstry, Steve, Weatherall, Mark, Beasley, Richard, Pilcher, Janine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834170/
https://www.ncbi.nlm.nih.gov/pubmed/27127650
http://dx.doi.org/10.1155/2016/7951272
_version_ 1782427453457694720
author Bibby, Susan
Reddy, Sumeet
Cripps, Terrianne
McKinstry, Steve
Weatherall, Mark
Beasley, Richard
Pilcher, Janine
author_facet Bibby, Susan
Reddy, Sumeet
Cripps, Terrianne
McKinstry, Steve
Weatherall, Mark
Beasley, Richard
Pilcher, Janine
author_sort Bibby, Susan
collection PubMed
description Objectives. Delivery of warmed, humidified air via nasal high flow therapy could potentially reduce replication of temperature-sensitive viruses in the upper respiratory tract. This study investigates whether nasal high flow therapy is well tolerated by healthy adults at 37°C and 41°C. Methods. In this randomised, double-blind, controlled crossover pilot trial, nasal high flow therapy was used to deliver humidified air at 35 L/min, at either 37°C or 41°C, for three one-hour sessions of use over one day. The alternative was delivered at least 14 days later. Ten healthy, nonsmoking adults were asked, via questionnaire after each day's use, whether they would use nasal high flow therapy while being unwell with a cold or flu if it was demonstrated to improve symptoms. Results. All participants completed both interventions. Eighty percent responded “yes” to future use of nasal high flow therapy, for both 37°C and 41°C. There was no significant change from baseline in saccharin times following either intervention or in the following morning. Conclusions. Delivering humidified air via nasal high flow therapy at both 37°C and 41°C is well tolerated by healthy adults. This supports investigation into the potential use of nasal high flow therapy as treatment in viral upper respiratory tract infections. Trial Registration. This trial is registered with ACTRN12614000183684 (tolerability study of nasal delivery of humidified & warmed air).
format Online
Article
Text
id pubmed-4834170
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48341702016-04-28 Tolerability of Nasal Delivery of Humidified and Warmed Air at Different Temperatures: A Randomised Double-Blind Pilot Study Bibby, Susan Reddy, Sumeet Cripps, Terrianne McKinstry, Steve Weatherall, Mark Beasley, Richard Pilcher, Janine Pulm Med Clinical Study Objectives. Delivery of warmed, humidified air via nasal high flow therapy could potentially reduce replication of temperature-sensitive viruses in the upper respiratory tract. This study investigates whether nasal high flow therapy is well tolerated by healthy adults at 37°C and 41°C. Methods. In this randomised, double-blind, controlled crossover pilot trial, nasal high flow therapy was used to deliver humidified air at 35 L/min, at either 37°C or 41°C, for three one-hour sessions of use over one day. The alternative was delivered at least 14 days later. Ten healthy, nonsmoking adults were asked, via questionnaire after each day's use, whether they would use nasal high flow therapy while being unwell with a cold or flu if it was demonstrated to improve symptoms. Results. All participants completed both interventions. Eighty percent responded “yes” to future use of nasal high flow therapy, for both 37°C and 41°C. There was no significant change from baseline in saccharin times following either intervention or in the following morning. Conclusions. Delivering humidified air via nasal high flow therapy at both 37°C and 41°C is well tolerated by healthy adults. This supports investigation into the potential use of nasal high flow therapy as treatment in viral upper respiratory tract infections. Trial Registration. This trial is registered with ACTRN12614000183684 (tolerability study of nasal delivery of humidified & warmed air). Hindawi Publishing Corporation 2016 2016-04-03 /pmc/articles/PMC4834170/ /pubmed/27127650 http://dx.doi.org/10.1155/2016/7951272 Text en Copyright © 2016 Susan Bibby et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Bibby, Susan
Reddy, Sumeet
Cripps, Terrianne
McKinstry, Steve
Weatherall, Mark
Beasley, Richard
Pilcher, Janine
Tolerability of Nasal Delivery of Humidified and Warmed Air at Different Temperatures: A Randomised Double-Blind Pilot Study
title Tolerability of Nasal Delivery of Humidified and Warmed Air at Different Temperatures: A Randomised Double-Blind Pilot Study
title_full Tolerability of Nasal Delivery of Humidified and Warmed Air at Different Temperatures: A Randomised Double-Blind Pilot Study
title_fullStr Tolerability of Nasal Delivery of Humidified and Warmed Air at Different Temperatures: A Randomised Double-Blind Pilot Study
title_full_unstemmed Tolerability of Nasal Delivery of Humidified and Warmed Air at Different Temperatures: A Randomised Double-Blind Pilot Study
title_short Tolerability of Nasal Delivery of Humidified and Warmed Air at Different Temperatures: A Randomised Double-Blind Pilot Study
title_sort tolerability of nasal delivery of humidified and warmed air at different temperatures: a randomised double-blind pilot study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834170/
https://www.ncbi.nlm.nih.gov/pubmed/27127650
http://dx.doi.org/10.1155/2016/7951272
work_keys_str_mv AT bibbysusan tolerabilityofnasaldeliveryofhumidifiedandwarmedairatdifferenttemperaturesarandomiseddoubleblindpilotstudy
AT reddysumeet tolerabilityofnasaldeliveryofhumidifiedandwarmedairatdifferenttemperaturesarandomiseddoubleblindpilotstudy
AT crippsterrianne tolerabilityofnasaldeliveryofhumidifiedandwarmedairatdifferenttemperaturesarandomiseddoubleblindpilotstudy
AT mckinstrysteve tolerabilityofnasaldeliveryofhumidifiedandwarmedairatdifferenttemperaturesarandomiseddoubleblindpilotstudy
AT weatherallmark tolerabilityofnasaldeliveryofhumidifiedandwarmedairatdifferenttemperaturesarandomiseddoubleblindpilotstudy
AT beasleyrichard tolerabilityofnasaldeliveryofhumidifiedandwarmedairatdifferenttemperaturesarandomiseddoubleblindpilotstudy
AT pilcherjanine tolerabilityofnasaldeliveryofhumidifiedandwarmedairatdifferenttemperaturesarandomiseddoubleblindpilotstudy